• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Donate Now
  • Sign Up

Center for Medicare Advocacy

Advancing Access to Medicare and Healthcare

  • Eligibility/Enrollment
  • Coverage/Appeals
    • Medicare Costs (2021)
    • Self Help Materials – Toolkits & More
  • Topics
    • Basic Introduction to Medicare
    • COVID-19 and Medicare
    • Medicare Costs (2021)
    • Home Health Care
    • Improvement Standard and Jimmo News
    • Nursing Home / Skilled Nursing Facility Care
    • Outpatient Observation Status
    • Part B
    • Part D / Prescription Drug Benefits
    • Medicare for People Under 65
    • Medicare “Reform”
    • All Other Topics
    • Resources
      • Infographics
  • Publications
    • CMA Alerts
    • Fact Sheets & Issue Briefs
    • Infographics
    • The Medicare Handbook
    • SNF Enforcement Newsletter
    • Elder Justice Newsletter
    • Medicare Facts & Fiction
    • Annual Report
    • Articles by Topic
  • Litigation
    • Litigation News
    • Cases
    • Litigation Archive
    • Amicus Curiae Activities
  • Newsroom
    • Press Releases
    • Editorials & Letters to the Editor
    • CMA Comments, Responses, and Letters
    • Medicare Facts & Fiction
    • CMA in the News
  • About Us
    • Mission Statement
    • CMA FAQs
    • Personnel & Boards
    • The Center for Medicare Advocacy Founder’s Circle
    • Connecticut Dually Eligible Appeals Project
    • Ossen Medicare Outreach, Education and Advocacy Project
    • National Medicare Advocates Alliance
    • National Voices of Medicare Summit
    • CMA Webinars
    • Products & Services
    • Testimonials
    • Career, Fellowship & Internship Opportunities
    • Contact Us
  • Support Our Work
    • Donate Now
    • Join the Center for Medicare Advocacy Founder’s Circle
    • Take Action
    • Share Your Health Care Story
    • Tell Congress to Protect Our Care
    • Listen to Medicare & Health Care Stories
    • Sign Up

Did CMS’s Partnership to Improve Dementia Care Reduce the Inappropriate Prescribing of Antipsychotic Drugs for Nursing Home Residents as Much as CMS Claims? Two Recent Studies Say No

June 28, 2018

Print Friendly, PDF & Email

The Centers for Medicare & Medicaid Services (CMS) has ended its campaign to reduce the inappropriate use of antipsychotic drugs for long-stay residents in nursing facilities (formally called the National Partnership to Improve Dementia Care in Nursing Homes) for facilities that reduced their antipsychotic drug usage by 34% by the end of 2016 (from 23.9% of long-stay residents in the first quarter of 2012 down to 15.7% of long-stay residents in the first quarter of 2017).  No more is expected of these facilities; CMS encourages them to “continue their efforts and maintain their success.”[1]  Only facilities not yet achieving the reduction – facilities that CMS now calls “late adopters” – have new Partnership goals; CMS encourages these facilities to reduce antipsychotic drug use by 15% by 2019.[2]  The American Health Care Association (AHCA), the largest nursing home trade association, also touts the reduction of antipsychotic drugs by its member facilities.[3]  Are these claims of victory – of actually reducing the use of these drugs – true?  Two recent studies say no; the claims of success are grossly overstated.

A study in the Journal of the American Medical Association Internal Medicine debunks claims that the National Partnership achieved its goals.[4]  First, the rate of antipsychotic drug use in nursing facilities was declining before the Partnership began (from 29% in 2006 to 22% in 2009-2010) so that the Partnership did not “accelerate[] the decline that was already occurring.”  Second, researchers found a lot of drug substitution.  Instead of antipsychotic drugs, residents were given other drugs, particularly mood stabilizers that are not captured in CMS assessment data.  Reviewers based their analysis on 637,426 residents (a 20% sample of nursing home residents using traditional Medicare between January 1, 2009 and December 31, 2014) and the Part D drugs they received.

Recent reports by CNN also confirm that drug substitution is occurring.  In October 2017, CNN reported that Avanir, the manufacturer of Nuedexta – a drug approved by the Food and Drug Administration to treat pseudobulbar affect, or PBS (uncontrollable laughing or crying), a condition affecting less than 1% of the population – targeted advertising at nursing facilities that had high rates of antipsychotic drug use.[5]  Since 2012, “more than half of all Nuedexta pills have gone to long-term care facilities” and “The number of pills rose to roughly 1.4 million in 2016, a jump of nearly 400% in just four years.”[6]  CNN reported that in March 2018, the Centers for Medicare & Medicaid Services issued a memorandum to Part D plans, reminding them, as described by CNN, that “Nuedexta is only approved to treat PBA” and that “Part D insurers are legally required to ensure the drug is only being covered when prescribed for medically-accepted uses.”[7] 

A second study found that the 20% reduction in the use of antipsychotic drugs was overstated because of the increased reporting of exclusionary diagnoses, chiefly schizophrenia.[8]  CMS excludes residents with schizophrenia (and also Tourettes and Huntingtons) from the publicly-reported quality measure that define inappropriate antipsychotic drug use.  Consequently, by including one of the three excluded diagnoses in residents’ assessments, facilities avoid being cited as administering inappropriate antipsychotic drugs.  The researchers conclude, “since antipsychotics prescribed to patients with schizophrenia, Tourette's syndrome, and Huntington's disease is not reported to CMS's quality measure, these findings suggest that a significant portion, perhaps as much as l/5th, of the apparent reduction in inappropriate antipsychotic use in nursing homes, is due to this trend in diagnosis reporting rather than an actual decrease in medication use.”  Researchers based their findings on resident assessment data for Medicaid beneficiaries in Virginia.  The National Institute of Mental Health reports that schizophrenia “is typically diagnosed in the late teen years to early 30s.”[9]  Consequently, the “new” diagnoses of schizophrenia in nursing home residents is likely to be false and fraudulent.    

Conclusion

Human Rights Watch reported in February that 179,000 nursing home residents are receiving antipsychotic drugs now.[10]  Other reports describe other rates of antipsychotic drug use.  Reports vary dramatically, depending on which residents are reviewed (long-stay, short-stay, all) and whether analysts look at residents during a Medicare Part A stay or residents receiving medications under Medicare Part D.[11]  

Regardless of how the numbers are calculated, however, there is no question that many tens of thousands of residents are getting antipsychotic drugs who should not be.  This problem is not solved, despite CMS’s, and the industry’s, claims of victory.

June 28, 2018 – T. Edelman.

 


[1] CMS, “Data show National Partnership to Improve Dementia Care achieves goals to reduce unnecessary antipsychotic medications in nursing homes” Fact Sheet (Oct. 2, 2017), https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-10-02.html.
[2] Id.  See also CMS, “National Partnership to Improve Dementia Care in Nursing Homes: Late Adopter Data Report (April 2018),” https://www.nhqualitycampaign.org/files/Late_adopter_package_20180416.pdf
[3] AHCA, New CMS Data Show Half of AHCA Members Hit 30 Percent Antipsychotics Reduction Goal Ahead of Schedule Association’s Quality Initiative drives drop in usage in skilled nursing centers nationwide” (News Release, May 5, 2016),  https://www.ahcancal.org/News/news_releases/Pages/New-CMS-Data-Show-Half-of-AHCA-Members-Hit-30-Percent-Antipsychotics-Reduction-Goal-Ahead-of-Schedule.aspx.
[4] Donovan T. Maust, H. Myra Kim, Claire Chiang, Helen C. Kales, “Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014,” JAMA Internal Medicine (published online Mar. 17, 2018), summary of article in May journal is at https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2674245. 
[5] Blake Ellis and Melanie Hicken, “The little red pill being pushed on the elderly: CNN investigation exposes inappropriate use of drug in nursing homes,” CNN (Oct. 12, 2017), https://www.cnn.com/2017/10/12/health/nuedexta-nursing-homes-invs/index.html.
[6] Id.
[7] Blake Ellis and Melanie Hicken, “Government issues warning about pill pushed on elderly,” CNN (Jun. 5, 2018), https://www.cnn.com/2018/06/04/health/nuedexta-government-warning-insurers-invs/index.html.
[8] Jonathan D. Winter, J. William Kerns, Katherine M. Winter & Roy T. Sabo (2017), “Increased Reporting of Exclusionary Diagnoses Inflate Apparent Reductions in Long-Stay Antipsychotic Prescribing,” Clinical Gerontologist DOI: 10.1080/07317115.2017.1395378 (published online Dec. 5, 2017), summary of article in journal is at https://www.tandfonline.com/doi/full/10.1080/07317115.2017.1395378.
[9] National Institute of Mental Health, Schizophrenia, https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml.
[10] Human Rights Watch, “They Want Docile How Nursing Homes in the United States Overmedicate People with Dementia” (Feb. 5, 2018), https://www.hrw.org/report/2018/02/05/they-want-docile/how-nursing-homes-united-states-overmedicate-people-dementia. 
[11] “Antipsychotic drugs and nursing home Residents: What Do the Different Numbers Mean?” (CMA Alert, Mar. 15, 2015), https://www.medicareadvocacy.org/antipsychotic-drugs-and-nursing-home-residents-what-do-the-different-numbers-mean/. 

Filed Under: Article Tagged With: alert, antipsychotics, Skilled Nursing Facility, Weekly Alert

Primary Sidebar

Easy Access to Understanding Medicare

The Center for Medicare Advocacy produces a range of informative materials on Medicare-related topics. Check them out:

  • Medicare Basics
  • CMA Alerts
  • CMA Webinars
  • Connecticut Info & Projects
  • Health Care Stories
  • Se habla Español

Sign Up for CMA Alerts

Jimmo v. Sebelius

Medicare covers skilled care to maintain or slow decline as well as to improve.

Improvement Isn’t Required. It’s the law!

Read more.

Medicare: Build Back Better

By prioritizing Medicare beneficiaries and the health systems that serve them, we can avoid drastic national consequences. The Center for Medicare Advocacy proposes a five-part plan that will make Medicare a bulwark against the worsening health and economic challenges facing the American people.

learn more.

Latest Tweets

  • .@CMAorg is grateful to @johnahartford for the many years of ongoing support and for sponsoring this year’s Sen. Ja… https://t.co/5m2bEvignf, Mar 5
@CMAorg

Footer

Stay Connected:

  • Contact Us
  • Sitemap
  • Products & Services
  • Copyright/Privacy

© 2021 · Center for Medicare Advocacy